Pharmahungary Group Press Release

Pharmahungary Group launches online version of miRNAtarget: new software tool for the analysis of mRNA targets of differentially expressed microRNAs (miRNAs).

Budapest, Hungary, March 13, 2018. Pharmahungary Group launches online version of miRNAtarget, www.mirnatarget.com. The new miRNA target-analysis service of Pharmahungary Group is able to analyze the targets of miRNAs from a network theoretical perspective and to predict the most probable mRNA targets of differentially expressed miRNAs. MIRNAtarget is a simple and powerful network theoretical approach to identify the most probable common targets of differentially expressed miRNAs relying on multiple miRNA-target interaction databases. “MIRNAtarget has several advantages e.g. increased coverage of possible miRNA-target interactions compared to experimentally validated databases” said Peter Ferdinandy, MD, PhD, MBA, Founder & CEO of Pharmahungary Group, a group of innovative R&D companies. “MIRNAtarget offers a novel, unbiased approach for drug target identification by utilizing miRNA transcriptomics data and analysis based on network theory and bioinformatics approach.” “MIRNAtarget is able to provide higher accuracy than currently available predicted miRNA-target interaction databases” said Bence Ágg, MD, Bioinformatics expert of Pharmahungary Group. “MIRNAtarget has been validated in two animal studies, manuscripts summarizing the results of the validation will be published soon in leading medical journals.” For more information on miRNAtarget please visit www.mirnatarget.com or contact us directly at businessdevelopment@pharmahungary.com.

The project was supported by the National Research, Development and Innovation Office of Hungary (NKFIA; NVKP-16-1-2016-0017 National Heart Program).

About Pharmahungary Group

Pharmahungary Group is an ISO 9001:2015 certified Hungarian SME developing innovative in-house R&D projects for valorization and providing preclinical and clinical R&D services since 2003.
- Preclinical R&D services: from in vitro to in vivo studies including custom designed, co-morbidity, and large animal models, e.g. Göttingen minipigs, focusing on but not limited to cardiovascular, metabolic, and renal disease models.
- Clinical R&D services: full management of clinical trials with Medical Devices including In Vitro Diagnostics, ATMPs, Investigator Initiated Trials, and niche trials that need strong scientific and regulatory consulting, e.g. clinical trials on sensitive patient population.
- In-house R&D projects: several IP protected drug development projects as well as novel supporting technologies for acute and chronic ischemic injuries, e.g. myocardial infarctions, heart failure, atherosclerosis

Contact Pharmahungary Group

Andras Nogradi, Business Development Manager, Graphisoft Park, Zahony str. 7., Budapest, H-1031, Hungary, European Union. e-mail: andras.nogradi@pharmahungary.com, cell: +36 30 7900017. More information: www.pharmahungary.com